Navigation Links
New Diabetes Research To Be Presented at FOCIS Annual Meeting
Date:6/4/2008

Federation of Clinical Immunology Societies presentations highlight important findings recognized by Juvenile Diabetes Research Foundation awards

BOSTON, June 4 /PRNewswire-USNewswire/ -- The Federation of Clinical Immunology Societies (FOCIS) announces the presentation of awards to two researchers recognizing significant findings related to advancement of Type 1 Diabetes research. The awards will be made following a research symposia on June 5, in conjunction with the 8th annual meeting of the Federation of Clinical Immunology Societies (FOCIS), being held at the Boston Marriott Copley Place, June 5-9. During the FOCIS annual meeting, an international representation of leading scientists will discuss recent advances in the understanding and treating of immune-mediated diseases in a series of 55 educational sessions presented to 1,200 researchers and physicians at FOCIS 2008. The Juvenile Diabetes Research Foundation (JDRF), in conjunction with FOCIS, is the sponsor of the special awards in the area of type 1 diabetes research.

Anti-CD20 therapy delays or prevents recurrent type 1 diabetes

This study, led by Changyun Hu, Yale University School of Medicine, New Haven, CT, shows that therapy with a monoclonal antibody to a marker on B lymphocytes leads to effective therapy of type 1 diabetes in a preclinical model. Similar therapies are known to be effective for some forms of cancer and other autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, and a current clinical trial sponsored by the National Institutes of Health is evaluating the comparable treatment in young adults newly diagnosed with autoimmune diabetes. Type 1 diabetes is an autoimmune disease where white cells of the immune system attack the insulin-producing beta cells. Current therapy with insulin does not address the underlying cause. The Yale group studied the mechanisms by which anti-CD20 therapy works in diabetes treatment, which has the potential for short-term therapy to lead to long-term benefits--even potential reversal of disease. Other investigators contributing to the new findings are from the University of Bristol, Bristol, United Kingdom.

Glucose levels can accelerate damage to insulin-producing cells

This study, led by Anna Skowera, King's College London, School of Medicine at Guy's, London, United Kingdom earned the second of the special research awards. Dr. Skowera's research identified a type of killer T lymphocyte which responds to a target comprised on a sequence within the precursor of insulin (called preproinsulin). They found that the target sequence is displayed at higher and higher levels by the insulin-producing beta cell as the glucose concentration around it goes up. In other words, the beta cell contributes to its own destruction when it tries to respond to high glucose levels by making more of this target sequence. The findings bring researchers closer to finding the elements causing of beta cell destruction and to strategies for the prevention of this destruction. One important implication of this study is that maintaining good glucose blood levels is very important for regulating the amount of beta cell damage. Other investigators contributing to the new findings include Min Zhao, Guo Cai Huang and Mark Peakman, also of King's College, London.

About Diabetes, JDRF, and FOCIS

Diabetes is the leading cause of kidney failure and adult blindness in the United States, and is the sixth leading cause of death, shortening life expectancy by an average of 7 to 10 years. Approximately 21 million Americans have diabetes, including 3 million with type 1 diabetes.

The JDRF is the leading charitable funder and advocate of type 1 (juvenile diabetes research worldwide. The mission of JDRF is to find a cure for diabetes and its complications through support of research.

FOCIS is a federation made up of 36 professional societies dedicated to improving human health through immunology. The FOCIS annual scientific meeting hosts delegates representing diverse specialties related to clinical immunology including allergy, dermatology, diabetes, genetics, multiple sclerosis, nephrology, oncology, pathology, transplantation and more. This four and one-half day symposium is an energetic working forum for the exchange of cutting-edge science and insights into autoimmune and inflammatory diseases.

For more information about FOCIS 2008 visit http://www.focisnet.org.

Contact: Gail Bast

FOCIS Executive Director

Email: gbast@focisnet.org

Cell: (414) 640-1635


'/>"/>
SOURCE Federation of Clinical Immunology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
2. Long-term pesticide exposure may increase risk of diabetes
3. Discovery of new signal pathway important to diabetes research
4. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
5. American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives
6. Medifast, Inc. to Present at the Canaccord Adams Diabetes & Obesity Conference
7. Metformin increases pathologic complete response rates in breast cancer patients with diabetes
8. International Diabetes Federation Commits to Improving Diabetes Education Globally Through Centres of Education
9. Panel Calls for Better Diabetes Screening
10. International Diabetes Federation grant supports study to prevent type 2 diabetes in India
11. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , ... the world with an estimated 5000 perioperative nurses in attendance to study ...
(Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
(Date:2/6/2016)... , ... February 06, 2016 , ... ... of eating disorder treatment helps to reduce the frequency and level of relapse. ... Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its fiscal year ... --> --> GAAP results: Revenue for ... $5.1 million or 4.1% from the third quarter of ... fourth quarter of 2014. Revenue for the year ended ...
(Date:2/4/2016)... 2016  Aethlon Medical, Inc. (Nasdaq: AEMD ... to treat life-threatening diseases, today announced results for ... 31, 2015. --> ... in our last quarterly call, we strategically advanced ... objective to establish the Aethlon Hemopurifier® as a ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology: